Should you be interested in the study participation, please contact us at: rberkovich.research@gmail.com
Currently Enrolling Studies
REMASTER:
Phase 3 Study of Remibrutinib in Secondary Progressive Multiple Sclerosis
Protocol # CLOU064P12301
Site: 5014
Sponsor: Novartis
ClinicalTrials.gov Identifier: NCT07225504
MONARCH:
Phase 3 Study of Orelabrutinib in Secondary Progressive Multiple Sclerosis
Protocol # ZB020-03-002
Site: 0125
Sponsor: Zenas BioPharma
ClinicalTrials.gov Identifier: NCT07299019
PriMroSe:
Phase 3 Study of Orelabrutinib in Primary Progressive Multiple Sclerosis
Protocol # ZB020-03-001
Site: 0125
Sponsor: Zenas BioPharma
ClinicalTrials.gov Identifier: NCT07067463
FREXCITE:
Phase 3 Study of Frexalimab in Relapsing and Secondary Progressive Multiple Sclerosis
Protocol # EFC18098
Site: 8400005
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT07325292
ENABLE:
Phase 4 Study of Ublituximab in Relapsing Multiple Sclerosis
Protocol # TG1101-RMS406
Site: WDA
Sponsor: TG Therapeutics
ClinicalTrials.gov Identifier: NCT06433752
COAST:
Phase 4 Study of Ozanimod in Relapsing Multiple Sclerosis
Protocol # 23-1686
Site: RGB
Sponsor: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT06529406
Ongoing Studies (enrollment closed)
FREXALT:
Phase 3 Study of Frexalimab in Relapsing Multiple Sclerosis
Protocol # EFC 17919
Site: 8400005
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT06141473
FREVIVA:
Phase 3 Study of Frexalimab in Progressive Multiple Sclerosis
Protocol # EFC 17504
Site: 8400005
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT06141486
REMODEL:
Phase 3 Study of Remibrutinib in Relapsing Multiple Sclerosis
Protocol # CLOU064C12302
Site: 5064
Sponsor: Novartis
ClinicalTrials.gov Identifier: NCT05156281
FILIOS:
Phase 3 Study of Ofatumumab in Relapsing and Progressive Multiple Sclerosis
Protocol # COMB157Q12301
Site: 5060
Sponsor: Novartis
ClinicalTrials.gov Identifier: NCT06869785
LTS17043
Phase 3 Study of Tolebrutinib in Relapsing Multiple Sclerosis
Protocol # NCT06372145
Site: 8400059
Sponsor: Sanofi
ClinicalTrials.gov Identifier: NCT06372145
ZENAS
Phase 2 Study of Obexelimab in Relapsing Multiple Sclerosis
Protocol # ZB012-02-002
Site: 1003
Sponsor: BioPharma
ClinicalTrials.gov Identifier: NCT06564311
ENSURE-1
Phase 3 Study of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Protocol # P3-IMU-838-RMS-01
Site: 100112
Sponsor: Immunic AG
ClinicalTrials.gov Identifier: NCT05134441